Aelis Farma

Focus: Aelis Farma is a French biotech company focused on cannabis addiction and psychosis treatments, with an emerging pipeline in Down syndrome. The company is publicly listed but operates at a modest scale with no current commercial products.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Aelis Farma

AI assessmentNot Hiring

No open roles listed right now. Follow Aelis Farma to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Bordeaux Maze Test

Down Syndrome

N/A

Clinical Trials (1)

NCT04241042Clinical Validation of the Bordeaux Maze Test

N/A

Help build intelligence for Aelis Farma

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to novel mechanisms in underserved indications (cannabis use disorder, psychosis) with limited competitive landscapes
Publicly listed status provides potential equity upside and financial stability versus early-stage private startups
Exposure to therapeutic areas with significant unmet medical need and societal relevance

Watch Out For

No marketed products or revenue generation signals early-stage execution risk and potential cash burn concerns
Currently zero active job openings indicates minimal hiring momentum or potential contraction phase
Limited published data (0 publications tracked) suggests early research stage and sparse scientific validation

Generated by Claude from Aelis Farma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Electroencephalography

Down Syndrome

N/A

Clinical Trials (1)

NCT04791124Assessment of Neural Oscillations in Adult Subjects With Down Syndrome and Typically Developing Subjects in Resting State and While Conducting Cognitive Tasks

N/A

AEF0117

Cannabis Use Disorder

Phase 2

Clinical Trials (5)

NCT05322941Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)

Phase 2

NCT03717272Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects

Phase 2

NCT03325595Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

Phase 1

+2 more

AEF0217

Down Syndrome

Phase 2

Clinical Trials (4)

NCT07334912AEF0217 in Participants With Down Syndrome

Phase 2

NCT05748405Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome

Phase 1/2

NCT05170737AEF0217 First-in-Human Phase I Study in 3 Parts (Single and Multiple Ascending Doses, and Food Effect) in Healthy Subjects.

Phase 1

+1 more

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 13 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo